Immunovant Inc

NASDAQ:IMVT   9:58:50 AM EDT
4.22
+0.05 (+1.20%)
Regulatory, Earnings Announcements

Immunovant Reports Q4 Loss Per Common Share Of $0.41

Published: 06/08/2022 12:44 GMT
Immunovant Inc (IMVT) - Immunovant Achieves Alignment With FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022.
Q4 Loss per Share $0.41.
Plans to Initiate 2 Placebo-controlled Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease in H2 of Cy 2022.
On Track to Initiate Pivotal Phase 3 Clinical Trial of Batoclimab in Myasthenia Gravis (mg), by End of June 2022.
Cash Balance of $494 Million As of March 31, 2022 Expected to Provide Cash Runway Into Calendar Year 2025.
Qtrly Loss per Common Share $0.41.
Q4 Earnings per Share View $-0.38 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.37

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.40

More details on our Analysts Page.